

AMENDMENTS

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in this application.

Listing of Claims:

Claims 1-24. Cancelled.

25. (Currently amended) A pharmaceutical ~~composition product~~, comprising a plurality of encapsulated products wherein the plurality of encapsulated products provide a therapeutically effective amount of venlafaxine HCl and each encapsulated product comprises:

- a) ~~a therapeutically effective amount of~~ venlafaxine HCl;
- b) at least one compressible material that is a carbohydrate, a polyol, a calcium salt, or mixtures thereof; and
- c) at least one lubricating material selected from the group consisting of fats, emulsifiers, waxes, ~~magnesium stearate, calcium stearate,~~ talc, ~~starches~~, silicon dioxide, and mixtures thereof; and

~~— d) a binder that is a polyvinylpyrrolidone polymer;~~

wherein;

each encapsulated product is processed using a tableting machine;

each encapsulated said product is in the form of a caplet having has a diameter from about 1 millimeter to about 3 millimeters and a length from about 1 millimeter to about 3 millimeters; and

the pharmaceutical composition provides controlled release of venlafaxine HCl.

26. Cancelled.

27. (Currently amended) The pharmaceutical ~~product~~ composition of claim 25, wherein said at least one lubricating material is present in an amount of up to about 5% by weight of the product.

28. (Currently amended) The pharmaceutical product of claim 25, wherein the venlafaxine HCl in the plurality of encapsulated products is present in an amount of about 0.001% to 70% by weight of the plurality of encapsulated products~~product~~.

29. (Currently amended) The pharmaceutical ~~product~~ composition of claim 25, wherein the polyol is sorbitol, isomalt, maltitol, xylitol, lactitol, microcrystalline celluloses, polydextrose, erythritols, sucrose, or mixtures thereof.

30. (Currently amended) The pharmaceutical ~~product~~ composition of claim 25, wherein the product is in the form of a caplet having a diameter of about 3 millimeters and a length of about 3 millimeters.

31. (Currently amended) The pharmaceutical ~~product~~ composition of claim 25, wherein the lubricating material forms a film around the pharmaceutical product.

32. (Currently amended) The pharmaceutical ~~product~~ composition of claim 31, wherein the film is a hydrophobic film.

33. (Currently amended) The pharmaceutical ~~product~~ composition of claim 25, wherein the pharmaceutical product further comprises polyvinyl acetate.

34. (Currently amended) The pharmaceutical ~~product~~ composition of claim 25, wherein the calcium salt is calcium phosphate, calcium carbonate, or calcium sulfonate.

35. (Currently amended) A pharmaceutical composition comprising a plurality of venlafaxine-containing caplets wherein the plurality of caplets provide caplet comprising a therapeutically-effective amount of venlafaxine-containing granules said granules comprising~~wherein~~:

the caplets are made by compressing a mixture comprising venlafaxine-containing granules and at least one lubricating material selected from the group consisting of fats, emulsifiers, waxes, talc, silicon dioxide, and mixtures thereof, wherein the granules comprise:

a) venlafaxine; and

b) at least one compressible material that is a carbohydrate, a polyol, a calcium salt, or mixtures thereof; and

wherein:

~~b) at least one lubricating material selected from the group consisting of fats, emulsifiers, waxes, magnesium stearate, calcium stearate, talc, starches, silicon dioxide, and mixtures thereof;~~

the pharmaceutical composition provides controlled release of venlafaxine HCl; and
~~— wherein the caplet is made by compressing the venlafaxine containing granules to give a~~
the caplet having caplets have a diameter from about 1 millimeter to about 3 millimeters and a length from about 1 millimeter to about 3 millimeters.

36. (New) A method of making a pharmaceutical composition comprising a plurality of encapsulated products wherein the plurality of encapsulated products provide a therapeutically effective amount of venlafaxine HCl, the method comprising:

a) mixing venlafaxine HCl with at least one compressible material that is a carbohydrate, a polyol, a calcium salt, or mixtures thereof to make a first mixture;

b) granulating the first mixture with a binder to make a granulate;

c) mixing the granulate with at least one lubricating material selected from the group consisting of fats, emulsifiers, waxes, talc, silicon dioxide, and mixtures thereof to make a second mixture; and

d) tableting the second mixture thereby producing the encapsulated product;

wherein:

the encapsulated product has a diameter from about 1 millimeter to about 3 millimeters and a length from about 1 millimeter to about 3 millimeters; and

the pharmaceutical composition provides controlled release of venlafaxine HCl.

37. (New) The pharmaceutical composition of claim 1, wherein the carbohydrate is a sugar, a cellulose or mixtures thereof.

38. (New) The pharmaceutical composition of claim 35, wherein the carbohydrate is a sugar, a cellulose or mixtures thereof.

39. (New) The method of claim 36, wherein the carbohydrate is a sugar, a cellulose or mixtures thereof.